|
|
|
 |
|
|
 |
 |
CEL-SCI Corporation
Company
Snapshot Purchase a Full Report on this Company
Business Description:
CEL-SCI Corporation. The Group's principal activity is to developed for the treatment of cancer. The Group manufactures the product Multikine TM using proprietary cell culture technologies that involve a combination of natural human interleukin-2 and certain other cytokines. Multikine is developed as a treatment for Human Papilloma Virus (HPV) induced cervical dysplasia in HIV infected women and for head and neck cancer. L.E.A.P.S. is another product, a T-cell modulation technology that is being tested as potential treatment and preventive vaccine against various diseases like AIDS, chronic genital and oral herpes, malaria, colon cancer, breast cancer and autoimmune myocarditis.
|
|
| |
Wright Quality Rating:
DBNN Rating Explanations |
| |
|
| |
|
| |
|
| |
|
| |
|
|
|
|
|
|
| |
| |
Stock Data: |
Recent Stock Performance: |
|
| |
Current Price (7/23/2010):
.52
(Figures in
U.S. Dollars) |
|
1 Week |
-3.0% |
|
13 Weeks |
1.0% |
|
|
|
|
|
|
|
|
|
4 Weeks |
-18.3% |
|
52 Weeks |
20.0% |
|
|
|
| |
| |
CEL-SCI Corporation
Key Data: |
|
|
|
| |
Ticker: |
CVM |
Country: |
UNITED STATES |
| |
|
| |
Exchanges: |
ASE |
Major Industry: |
Drugs, Cosmetics & Health Care |
| |
|
| |
|
|
Sub Industry: |
Ethical Drug Manufacturers |
| |
|
| |
2009
Sales |
80,093
(Year Ending Jan 2010). |
Employees: |
29 |
| |
|
| |
Currency: |
U.S. Dollars |
Market Cap: |
105,400,720 |
| |
|
| |
Fiscal Yr Ends: |
September |
Shares Outstanding: |
204,661,592 |
| |
|
| |
Share Type: |
Common |
Closely Held Shares: |
6,528,225 |
|
| |
|
| |
| |
|
|
|
|
| |
Purchase a Full Subscription to All Reports From CorporateInformation: |
|
|
|
| |
The following reports, available for CEL-SCI Corporation, are typical of the content provided on all companies
covered in CorporateInformation.com
Basic Reports
CEL-SCI Corporation company Profile (Business Description, Price/Earnings, Price/Sales,
Price/Book, Dividend Yield, Company Officers, Contact Information), Competitor Analysis and up to ten-year history of Sales, Earnings per Share,
Dividends per Share, Security Price and Key Ratios. View Samples
Financial Statement Reports
Research reports that analyze CEL-SCI Corporation Income Statement and Balance Sheet along with
the Sources of Capital for a five-year period. View Samples
Financial Ratio Reports
Analyses reports that highlight CEL-SCI Corporation
Accounting Ratios, Asset Utilization, Fixed Charges Coverage, Liquidity, Leverage, Profitability,
Employee Efficiency and Per-Share Data over a five-year period. View Samples
Wright Quality Analyses Reports
Wright’s proprietary rating of corporate quality. The reports include a detailed
analysis of CEL-SCI Corporation Equity, Liquidity, Financial Strength,
Profitability and Corporate Growth. View Samples |
| |
|
|
| |
|
|
|
 |
|
|
|
|
|
|
|
CorporateInformation® website and selected data Copyright © 2000 -
by The Winthrop Corporation. All Rights Reserved. Except for quotations by established
news media, no pages on this site may be reproduced, stored in a retrieval system,
or transmitted for commercial purposes, in any form or by any means, electronic,
mechanical, photocopying, recording, or otherwise without prior written permission.
Information is believed reliable, but accuracy, completeness and opinions are not
guaranteed.
|
|
|
|